Stockreport

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential [Seeking Alpha]

Larimar Therapeutics, Inc.  (LRMR) 
PDF Follow Play 12min Summary Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progr [Read more]